The Supreme Court sided with Generic companies in a patent dispute over Galvus (Vildagliptin), a DPP-4 inhibitor-based diabetes treatment.

On the morning of the 28th, the Supreme Court dismissed Novartis' appeal against Ahn-Gook Pharmaceutical and Hanmi Pharmaceutical to invalidate the extension of the patent duration. There is a problem with the reason for the appeal claimed by Novartis. Generics succeeded in invalidating 55 days of the material patent duration.

Ahn-Gook and Hanmi Pharmaceutical began early launch of generics for Galvus in accordance with the ruling. Generic is likely to be released early next year. The issue of this case is which period of the "extended duration" of th